498 related articles for article (PubMed ID: 25455994)
1. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
2. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
[TBL] [Abstract][Full Text] [Related]
4. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
[TBL] [Abstract][Full Text] [Related]
5. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
6. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
8. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
Broner EC; Tropé CG; Reich R; Davidson B
Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
[TBL] [Abstract][Full Text] [Related]
9. Expression of Nestin and CD133 in serous ovarian carcinoma.
Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions.
Elloul S; Vaksman O; Stavnes HT; Trope CG; Davidson B; Reich R
Clin Exp Metastasis; 2010 Mar; 27(3):161-72. PubMed ID: 20213325
[TBL] [Abstract][Full Text] [Related]
11. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.
Slipicevic A; Holth A; Hellesylt E; Tropé CG; Davidson B; Flørenes VA
Gynecol Oncol; 2014 Oct; 135(1):118-24. PubMed ID: 25093290
[TBL] [Abstract][Full Text] [Related]
12. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
Kenda Suster N; Smrkolj S; Virant-Klun I
J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
[TBL] [Abstract][Full Text] [Related]
13. MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma.
Nymoen DA; Slipicevic A; Holth A; Emilsen E; Hetland Falkenthal TE; Tropé CG; Reich R; Flørenes VA; Davidson B
Hum Pathol; 2016 Aug; 54():74-81. PubMed ID: 27063471
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer.
Figiel S; Vasseur C; Bruyere F; Rozet F; Maheo K; Fromont G
Hum Pathol; 2017 Mar; 61():26-32. PubMed ID: 27818287
[TBL] [Abstract][Full Text] [Related]
15. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
16. Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; Holth A; Dong HP
Virchows Arch; 2020 Nov; 477(5):677-685. PubMed ID: 32472195
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma.
Zhou YM; Cao L; Li B; Zhang RX; Sui CJ; Yin ZF; Yang JM
Ann Surg Oncol; 2012 May; 19(5):1700-6. PubMed ID: 21584833
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors.
Solheim O; Førsund M; Tropé CG; Kraggerud SM; Nesland JM; Davidson B
APMIS; 2017 Sep; 125(9):781-786. PubMed ID: 28585395
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms.
Cho EY; Choi Y; Chae SW; Sohn JH; Ahn GH
Pathol Int; 2006 Feb; 56(2):62-70. PubMed ID: 16445817
[TBL] [Abstract][Full Text] [Related]
20. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
